This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wenxia Chai Articles by Danser, A. J. Search for Related Content PubMed PubMed Citation Articles by Wenxia Chai, Articles by Danser, A. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Social Bookmarking                         What's this?

Cardiac aldosterone in subjects with hypertrophic cardiomyopathy

Department of Clinical Genetics, Erasmus MC

Yvonne M Hoedemaekers

Department of Clinical Genetics, Erasmus MC

Ron HN van Schaik

Department of Clinical Chemistry, Erasmus MC

Marianne van Fessem

Department of Clinical Chemistry, Erasmus MC

Ingrid M Garrelds

Department of Clinical Genetics, Erasmus MC

Jasper J Saris

Department of Clinical Genetics, Erasmus MC

Dennis Dooijes

Department of Clinical Genetics, Erasmus MC

Folkert J ten Cate

Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands

Marcel MJ Kofflard

Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands

AH Jan Danser

Department of Pharmacology, Erasmus MC, a.danser{at}erasmusmc.nl

Left ventricular (LV) hypertrophy in subjects with hypertrophic cardiomyopathy (HCM) is variable, suggesting a role for modifying factors. Here, we determined whether aldosterone modulates hypertrophy in HCM. Cardiac and/or plasma aldosterone were measured in organ donors and HCM patients.The effect of the aldosterone synthase (CYP11B2 ) C-344T polymorphism on LV mass index (LVMI) and interventricular septum thickness (IVS) was determined in 79 genetically independent subjects with HCM. Aldosterone in HCM hearts and plasma was similar to that in normal hearts and plasma. In HCM women, no associations between CYP11B2 genotype and any of the measured parameters were observed, whereas in HCM men, LVMI increased with the presence of the T allele. Similar T allele-related increases were observed for IVS. Multiple regression analysis revealed that the T allele-related effect on IVS occurred independently of renin, the ACE I/D polymorphism, the AT₁-receptor A/C 1166 polymorphism and the AT -receptor A/C 3123 polymorphism. In conclusion, circulating and cardiac aldosterone are normal in HCM, thereby arguing against selectively increased cardiac aldosterone production in HCM.Thus, the association between the CYP11B2 C-344T polymorphism and hypertrophy in HCM most likely relates to the T allele-related increases in circulating aldosterone.This finding raises the need for studies determining the benefit of aldosterone blockade in HCM.

Key Words: aldosterone • hypertrophy • polymorphism • angiotensin • gender

References

• Maron BJ Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.[Abstract/Free Full Text]
• Marian AJ, Salek L., Lutucuta S. Molecular genetics and pathogenesis of hypertrophic cardiomyopathy. Minerva Med 2001;92:435-51.[Medline] [Order article via Infotrieve]
• Marian AJ Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355:58-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• van Kesteren CAM, van Heugten HAA, Lamers JMJ, Saxena PR, Schalekamp Madh, Danser AHJ. Angiotensin II-mediated growth and antigrowth effects in cultured neonatal rat cardiac myocytes and fibroblasts. J Mol Cell Cardiol 1997;29:2147-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Osterop Aprm, Kofflard MJM, Sandkuijl et al. AT1 receptor A/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 1998;32:825-30.[Abstract/Free Full Text]
• Deinum J., van Gool JMG, Kofflard MJM, ten Cate FJ, Danser AHJ. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001;38:1278-81.[Abstract/Free Full Text]
• Tsybouleva N., Zhang L., Chen S. et al. Aldosterone through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:1284-91.[Abstract/Free Full Text]
• Chai W., Garrelds IM, Arulmani U., Schoemaker RG, Lamers JMJ, Danser AHJ. Genomic and non-genomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective? Br J Pharmacol 2005;145:664-71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lombès M., Alfaidy N., Eugene E., Lessana A., Farman N., Bonvalet JP Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.[Abstract/Free Full Text]
• van Kats JP, Duncker DJ, Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1-receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000;102:1556-63.[Abstract/Free Full Text]
• Gomez-Sanchez EP, Ahmad N., Romero DG, Gomez-Sanchez CE Origin of aldosterone in the rat heart. Endocrinology 2004;145:4796-802.[Abstract/Free Full Text]
• Silvestre JS, Robert V., Heymes C. et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.[Abstract/Free Full Text]
• Fiebeler A., Nussberger J., Shagdarsuren E. et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005;111:3087-94.[Abstract/Free Full Text]
• Chai W., Garrelds IM, de Vries R., Danser AHJ. Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone? Hypertension 2006;47:665-70.[Abstract/Free Full Text]
• Stella P., Bigatti G., Tizzoni L. et al. Association between aldosterone synthase (CYP11B2) polymorphism and left ventricular mass in human essential hypertension. J Am Coll Cardiol 2004;43:265-70.[Abstract/Free Full Text]
• Barbato A., Russo P., Siani A. et al. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population. J Hypertens 2004;22:1895-901.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schunkert H., Hengstenberg C., Holmer SR et al. Lack of association between a polymorphism of the aldosterone synthase gene and left ventricular structure. Circulation 1999;99:2255-60.[Abstract/Free Full Text]
• Brand E., Chatelain N., Mulatero P. et al. Structural analysis and evaluation of the aldosterone synthase gene in hypertension. Hypertension 1998;32:198-204.[Abstract/Free Full Text]
• Hautanena A., Lankinen L., Kupari M. et al. Associations between aldosterone synthase gene polymorphism and the adrenocortical function in males. J Intern Med 1998;244:11-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Maron BJ, Epstein SE Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol 1979;43:1242-4.Vletter[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• van der Lee C., Kofflard MJM, van Herwerden LA, Vletter WB, ten Cate FJ Sustained improvement after combined anterior 2088-92. mitral leaflet extension and myectomy in hypertrophic obstructive cardiomyopathy. Circulation 2003;108: 2088-92.[Abstract/Free Full Text]
• Wigle ED, Rakowski H., Kimball BP, Williams WG Hypertrophic cardiomyopathy. Clinical spectrum and treatment. Circulation 1995;92:1680-92.Clinical spectrum and treatment.[Free Full Text]
• Derkx FHM, de Bruin RJA, van Gool JM et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996;42:1051-63.[Abstract/Free Full Text]
• Danser AHJ, van Kesteren CAM, Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-6.[Abstract/Free Full Text]
• Patel R., Lim DS, Reddy D. et al. Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol 2000;32:2369-77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kocks MJ, Titia Lely A., Boomsma F., de Jong PE, Navis G. Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1-7) in healthy man. J Hypertens 2005;23:597-602.[Web of Science][Medline] [Order article via Infotrieve]
• Danser AHJ, Derkx FHM, Schalekamp Madh, Hense HW, Riegger GAJ, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998;16:853-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de Lannoy LM, Schuijt MP, Saxena PR, Schalekamp Madh, Danser AHJ. Angiotensin-converting enzyme is the main contributor to angiotensin I-II conversion in the interstitium of isolated perfused rat heart. J Hypertens 2001;19:959-65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schuijt MP, van Kats JP, de Zeeuw S. et al. Cardiac interstitial fluid levels of angiotensin I and II in the pig. J Hypertens 1999;17:1885-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Tesson F., Dufour C., Moolman JC et al. The influence of the angiotensin I converting enzyme genotype in familial hypertrophic cardiomyopathy varies with the disease gene mutation. J Mol Cell Cardiol 1997;29:831-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pojoga L., Gautier S., Blanc H. et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998;11:856-60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Schunkert H., Hense HW, Muscholl M. et al. Associations between circulating components of the renin angiotensin aldosterone system and left ventricular mass. Heart 1997; 77:24-31.[Abstract/Free Full Text]
• Sun Y., Zhang J., Lu L., Chen SS, Quinn MT, Weber KT Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 2002;161:1773-81.[Abstract/Free Full Text]
• Ahokas RA, Sun Y., Bhattacharya SK, Gerling IC, Weber KT Aldosteronism and a proinflammatory vascular phenotype: role of Mg2+, Ca2+, and H2O2 in peripheral blood mononuclear cells. Circulation 2005;111:51-7.[Abstract/Free Full Text]
• Glorioso N., Filigheddu F., Parpaglia PP et al. 11betaP Hydroxysteroid dehydrogenase type 2 activity is associated with left ventricular mass in essential hypertension. Eur Heart J 2005;26:498-504.[Abstract/Free Full Text]
• Keavney B., Mayosi B., Gaukrodger N. et al. Genetic variation at the locus encompassing 11-beta hydroxylase and aldosterone synthase accounts for heritability in cortisol precursor (11-deoxycortisol) urinary metabolite excretion. J Clin Endocrinol Metab 2005;90:1072-7.[Abstract/Free Full Text]
• Ganapathipillai S., Laval G., Hoffmann IS et al. CYP11B2-CYP11B1 haplotypes associated with decreased 11 beta-hydroxylase activity. J Clin Endocrinol Metab 2005;90:1220-5.[Abstract/Free Full Text]
• Hilgers KF, Schmidt BM Gene variants of aldosterone synthase and hypertension. J Hypertens 2005;23:1957-9.[Web of Science][Medline] [Order article via Infotrieve]
• White PC, Rainey WE Editorial: polymorphisms in CYP11B genes and 11-hydroxylase activity. J Clin Endocrinol Metab 2005;90:1252-5.[Free Full Text]
• Xiao F., Puddefoot JR, Barker S., Vinson GP Mechanism for aldosterone potentiation of angiotensin II-stimulated rat arterial smooth muscle cell proliferation. Hypertension 2004;44:340-5.[Abstract/Free Full Text]
• Jaffe IZ, Mendelsohn ME Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells. Circ Res 2005;96:643-50.[Abstract/Free Full Text]
• Mazak I., Fiebeler A., Müller DN et al. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation 2004;109:2792-800.[Abstract/Free Full Text]
• Liu SL, Schmuck S., Chorazcyzewski JZ, Gros R., Feldman RD Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 2003;108:2400-06.[Abstract/Free Full Text]
• Schunkert H., Danser AHJ, Hense HW, Derkx FHM, Kürzinger S., Riegger GAJ. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95:39-45.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 4, 225-230 (2006)
DOI: 10.3317/jraas.2006.042


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Wenxia Chai Articles by Danser, A. J. Search for Related Content PubMed PubMed Citation Articles by Wenxia Chai, Articles by Danser, A. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Cardiomyopathy Social Bookmarking                         What's this?